Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03511664 is registered in ClinicalTrials.gov with Endocyte as lead sponsor.

NCT NCT03511664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03511664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Endocyte
Phase
Phase 3
Overall status
Completed
Start date
May 29, 2018
Completion date
December 14, 2023
Enrollment
861 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer